Elizabeth. Tomlinson, et.al., Transgenic mice expressing human fibroblast growth factor-19 display increased metabolic rate and decreased adiposity., Endocrinology, 2002, 143

http://rdf.ncbi.nlm.nih.gov/pubmed/11956156

Elizabeth. Tomlinson, et.al., Transgenic mice expressing human fibroblast growth factor-19 display increased metabolic rate and decreased adiposity., Endocrinology, 2002, 143

pubmed

allele

http://purl.org/net/cito/citesAsAuthority

• Tg(Myl2-FGF19)1Dfre
  http://metadb.riken.jp/db/mgi_rdf/MGI:3510921

表現型アノテーション

http://purl.org/net/cito/citesAsAuthority

• increased energy expenditure_Tg(Myl2-FGF19)1Dfre/?
  http://metadb.riken.jp/0004889IFVBTgMyl2FGF191DfreTgMyl2FGF191Dfre
• increased food intake_Tg(Myl2-FGF19)1Dfre/?
  http://metadb.riken.jp/0011939IFVBTgMyl2FGF191DfreTgMyl2FGF191Dfre
• improved glucose tolerance_Tg(Myl2-FGF19)1Dfre/?
  http://metadb.riken.jp/0005292IFVBTgMyl2FGF191DfreTgMyl2FGF191Dfre
• increased basal metabolism_Tg(Myl2-FGF19)1Dfre/?
  http://metadb.riken.jp/0008965IFVBTgMyl2FGF191DfreTgMyl2FGF191Dfre
• increased insulin sensitivity_Tg(Myl2-FGF19)1Dfre/?
  http://metadb.riken.jp/0002891IFVBTgMyl2FGF191DfreTgMyl2FGF191Dfre
• decreased circulating insulin-like growth factor I level_Tg(Myl2-FGF19)1Dfre/?
  http://metadb.riken.jp/0004701IFVBTgMyl2FGF191DfreTgMyl2FGF191Dfre
• decreased triglyceride level_Tg(Myl2-FGF19)1Dfre/?
  http://metadb.riken.jp/0005318IFVBTgMyl2FGF191DfreTgMyl2FGF191Dfre
• decreased circulating glucagon level_Tg(Myl2-FGF19)1Dfre/?
  http://metadb.riken.jp/0002696IFVBTgMyl2FGF191DfreTgMyl2FGF191Dfre
• decreased body weight_Tg(Myl2-FGF19)1Dfre/?
  http://metadb.riken.jp/0001262IFVBTgMyl2FGF191DfreTgMyl2FGF191Dfre
• abnormal energy homeostasis_Tg(Myl2-FGF19)1Dfre/?
  http://metadb.riken.jp/0005448IFVBTgMyl2FGF191DfreTgMyl2FGF191Dfre
• decreased retroperitoneal fat pad weight_Tg(Myl2-FGF19)1Dfre/?
  http://metadb.riken.jp/0009305IFVBTgMyl2FGF191DfreTgMyl2FGF191Dfre
• decreased circulating leptin level_Tg(Myl2-FGF19)1Dfre/?
  http://metadb.riken.jp/0005668IFVBTgMyl2FGF191DfreTgMyl2FGF191Dfre
• increased brown adipose tissue amount_Tg(Myl2-FGF19)1Dfre/?
  http://metadb.riken.jp/0000005IFVBTgMyl2FGF191DfreTgMyl2FGF191Dfre
• decreased epididymal fat pad weight_Tg(Myl2-FGF19)1Dfre/?
  http://metadb.riken.jp/0009289IFVBTgMyl2FGF191DfreTgMyl2FGF191Dfre
• increased oxygen consumption_Tg(Myl2-FGF19)1Dfre/?
  http://metadb.riken.jp/0005289IFVBTgMyl2FGF191DfreTgMyl2FGF191Dfre
• abnormal liver morphology_Tg(Myl2-FGF19)1Dfre/?
  http://metadb.riken.jp/0000598IFVBTgMyl2FGF191DfreTgMyl2FGF191Dfre
• decreased liver triglyceride level_Tg(Myl2-FGF19)1Dfre/?
  http://metadb.riken.jp/0009356IFVBTgMyl2FGF191DfreTgMyl2FGF191Dfre
• decreased susceptibility to diet-induced obesity_Tg(Myl2-FGF19)1Dfre/?
  http://metadb.riken.jp/0005659IFVBTgMyl2FGF191DfreTgMyl2FGF191Dfre
• decreased circulating glucose level_Tg(Myl2-FGF19)1Dfre/?
  http://metadb.riken.jp/0005560IFVBTgMyl2FGF191DfreTgMyl2FGF191Dfre
• decreased total body fat amount_Tg(Myl2-FGF19)1Dfre/?
  http://metadb.riken.jp/0010025IFVBTgMyl2FGF191DfreTgMyl2FGF191Dfre
• increased body temperature_Tg(Myl2-FGF19)1Dfre/?
  http://metadb.riken.jp/0005533IFVBTgMyl2FGF191DfreTgMyl2FGF191Dfre
• decreased circulating insulin level_Tg(Myl2-FGF19)1Dfre/?
  http://metadb.riken.jp/0002727IFVBTgMyl2FGF191DfreTgMyl2FGF191Dfre

class

http://purl.org/net/cito/citesAsAuthority

• Tg(Myl2-FGF19)1Dfre
  http://metadb.riken.jp/db/mgi_rdf/MGI:3510921